Composition containing DNA coding for a ribozyme and an oligonucleotide substrate, and method for measuring transcription rates

ABSTRACT

Compositions (reporter systems), which contain a ribozyme-encoding DNA sequence and an oligonucleotide substrate that is cleaved by the ribozyme transcribed by the DNA sequence, are described. In a preferred embodiment, the oligonucleotide substrate is labeled by a fluorophore group (reporter group) and a fluorescence-quenching group (quencher group), the fluorescence of the fluorophore being prevented from being quenched by the fluorescence-quenching group after cleavage by the ribozyme has taken place, and therefore a fluorescence signal is generated. Moreover, methods for measuring transcription rates, for instance for determining transcription-inhibitors or transcription activators, are described.

This application is the national phase under 35 U.S.C. § 371 of PCTInternational Application No. PCT/EP99/01776 which has an Internationalfiling date of Mar. 17, 1999, which designated the United States ofAmerica.

The present invention relates to compositions (reporter systems)containing a DNA sequence encoding a ribozyme, preferably a hammerheadribozyme, and a oligonucleotide substrate which is cleaved by theribozyme transcribed by the DNA sequence. In a preferred embodiment, aFRET oligonucleotide is used, i.e. an oligonucleotide substrate which islabeled with a fluorophore group (reporter group) and afluorescence-quenching group (quenching group), wherein the fluorescenceof the fluorophore is prevented from being quenched by thefluorescence-quenching group after cleavage by the ribozyme has takenplace, and therefore a fluorescence signal is generated. Moreover, thepresent invention relates to methods for measuring-transcription rates,for instance for determining transcription inhibitors or transcriptionactivators, with the use of the composition of the invention, andmethods for measuring the catalytic activity of ribozymes.

As a rule, the mechanisms of eukaryotic and prokaryotic transcriptionare examined by methods by which the mRNA is synthesized in vitro (invitro transcription) in a cell free system, that is to say with the useof correspondingly processed cell extracts. For the production oftranscripts, specifically developed transcription vectors which alsocarry the promoter for a corresponding RNA polymerase in addition to thereporter gene are used in this process. For instance, if the influenceof particular transcription activators on the transcription is to beexamined, the mRNA of the coding reporter gene must be detectable andquantifiable with suitable methods. For this purpose, radioactivelylabeled nucleoside triphosphates which are incorporated into theresulting mRNA, are in general added to the cell extract. Theradioactively labeled mRNA is then isolated from the cell extract,electrophoretically separated on a polyacrylamide gel and visualized andquantified by autoradiography (T. Maniatis, E. Fritsch, J. Sambrook,Molecular cloning: A Laboratory Manual, Cold Spring Harbor LaboratoryPress, New York (1982) 6.45). An alternative method, the so-calleddot-hybridization technique, uses radioactively labeled RNA probes todetect the in vitro transcribed mRNAs (J. Flores et al., Lancet 1(1983), 555-558). In principle, there also exists the possibility ofdetecting transcription indirectly via the activity of the luciferaseenzyme, wherein the transcription of the luciferase reporter gene iscoupled to an in-vitro translation system. The disadvantages of theabove-described and partly routinely used assay methods are inparticular the use of larger amounts of radioactively labeled nucleosidetriphosphates and/or the high amount of methodical work and timeinvolved in the quantification of the RNA transcripts. More suitablemethods for a direct, fast and sensitive measurement of transcriptionrates are, however, of interest not only for scientific questions, butalso for the biotechnological industry. For instance, in the so-calledhigh throughput screening combinatory substance libraries are screenedfor potential guiding structures which influence the transcription ofparticular therapeutically relevant target genes. For these and similarapplications too, a technically simple, sensitive assay system wouldconstitute a great progress, as there are no satisfactory solutions sofar.

Thus, the present invention is based on the problem of providing methodsand systems suitable for these methods which permit a simple andsensitive measurement of transcription rates.

This technical problem is solved by the embodiments characterized in thepatent claims. It has been found that the composition of the invention(reporter system) surprisingly allows the above-mentioned problems to becircumvented. This system has the following advantages inter alia:

Direct detection of the mRNA in the cell extract.

Fast, reproducible and technically simple quantification oftranscription rates, for instance via automated fluorescencemeasurement.

Highly sensitive and highly specific detection of even the smallestamounts of RNA transcripts (catalytic principle for signalintensification).

Simple control of the course of transcription, for instance bytime-dependent fluorescence measurement (real time analytics).

Thus, the present invention relates to a composition containing

(a) a ribozyme-encoding DNA sequence which is operatively linked to apromoter and/or regulatory elements; and

(b) an oligonucleotide substrate which is cleaved by the ribozymetranscribed by the DNA from (a),

with a directly measurable signal being generated after cleavage, as thecleaved oligonucleotide substrate can be distinguished from thenon-cleaved oligonucleotide substrate.

The expression “ribozymes” as used herein relates to catalytic RNAmolecules capable of cleaving other RNA molecules at phosphodiesterbonds in a manner specific to the sequence. Here, the hydrolysis of thetarget sequence to be cleaved is always initiated by the formation of acatalytically active complex consisting of ribozyme and substrate RNA.After cleavage, the hydrolyzed substrate oligonucleotide dissociatesfrom the ribozyme; the latter is then available for further reactions.

In principle, all ribozymes capable of cleaving phosphodiester bonds intrans, that is to say intramolecularly, are suitable for the purposes ofthe invention. Apart from ribonuclease P (C. Guerrier-Takada et al.,Cell 44 (1983) 849-857) the known naturally occurring ribozymes(hammerhead ribozyme, hairpin ribozyme, hepatitis delta virus ribozyme,Neurospora mitochondrial VS ribozyme, group I and group II introns) arecatalysts, which, however, cleave or splice themselves and which act incis (intramolecularly) (review article in P. Turner (editor), Ribozymeprotocols, Humana press (1997), 1-9). By separating the catalytic unitfrom the sequence containing the cleavage site it was in all casespossible to obtain ribozyme variants cleaving in trans: the hammerheadribozyme (J. Haselhoff and W. Gerlach, Nature 334 (1988), 585-591);hairpin ribozyme (A. Hampel and R. Tritz, Biochemistry 28 (1989),4929-4933); the hepatitis delta ribozyme (M. Been, Trends Biochem. Sci.19 (1994) 251-256): the Neurospora mitochondrial VS ribozyme (H. Guo etal., J. Mol. Biol. 232 (1993) 351-361); the group I intron fromtetrahymena (Zaug et al., Nature 324 (1986) 429-433; the group 11 intron(S. Augustin et al., Nature 34 (1990) 383-386).

The term “promoter” as used herein relates to any DNA sequence by whichthe transcription of the DNA sequence operatively linked thereto iscontrolled via the corresponding RNA polymerase in vivo (or in vitro) inprokaryotic or eukaryotic systems. Such promoters are known to a skilledperson and for instance include PolII promoters, SP6, T3 and T7promoters. The endogenous ribozyme expression in eukaryotic cells orcell extracts can, for instance, be carried out by insertion of theribozyme-encoding DNA sequence into the non-translated region of geneswhich are transcribed by the RNA polymerase II and are under the controlof highly transcribing promoters. Examples include viral promoters, suchas the early SV40 promoter (F. Cameron and P. Jennings, Proc. Natl.Acad., Sci., USA 86 (1989) 9139-9143), the promoter of the actin gene(N. Sarver et al., Science 247 (1990) 1222-1225) or a retroviral longterminal repeat, such as HIV-LTA (Koizumi et al., Gene 117 (1992),179-184).

In a preferred embodiment of the invention, the ribozyme is a hammerheadribozyme. The hammerhead ribozyme measuring only about 30 nucleotides inlength is one of the smallest known ribozymes catalyzing thesite-specific hydrolysis of phosphodiester bonds (review article: K.Birikh et al., Eur. J. Biochem. 245 (1997) 1-16). The ribozyme structurecomprises three double-stranded areas (helices I, II and III), flankingthe cleavable phosphodiester bond, and two highly conservedsingle-stranded sequences (O. Uhlenbeck, Nature 328 (1987), 596-600). Byseparating the catalytic core sequence from a sequence containing thecleavage site it was possible to prepare ribozyme variants capable ofcleaving nearly any target RNA in trans under physiological conditions(J. Haselhoff and W. Gerlach, Nature 334 (1988), 585-591).

In connection with the very promising therapeutical possibilities ofusing hammerhead ribozymes, hammerhead ribozymes have recently beensuccessfully optimized in respect of their kinetic properties (highconversion rates), sequence length (minimal motifs) and substratespecificities. Review articles on this topic are for instance Birikh,Eur. J. Biochem. 245 (1997), 1-16; Burke, Nature Biotech. 15 (1997),414-415 and Eckstein, Lilley (editors) Nucleic Acids and MolecularBiology 10, Springer publishers (1996), 173-329.

In a preferred embodiment, the above-mentioned promoters can beregulated, i.e. they can for instance be activated by transcriptionactivators or inhibited by particular compounds. Genes of eukaryots andprokaryots differ considerably from each other in respect of theorganization of the transcription unit (H. Ibelgaufts, Gentechnologievon A bis Z, VCH publishers Weinheim (1990), 219-223). The 5′-flankingarea of a eukaryotic gene is often termed promoter region, as itcontains a number of distinct DNA sequence elements participating in thecontrol of gene expression. They include the TATA box and initiatorsequence, inter alia, which together form the core promoter. The basaltranscription is essentially regulated by the basic transcriptionactivators of class II (TF II A, B, D, E, F, H and Pol II). In analogyto basal transcription, the term “activated transcription” is used whereadditional regulatory elements influence transcription. Activationoccurs primarily by a binding of transcription activators to so-called“upstream activating sequences” (UAS). Examples of activatedtranscription are: SP1 which binds to the SP1 binding site, CREB whichbinds to the CRE element.

As described herein in more detail, the choice of suitable promoters ina suitable test system allows compounds which activate or inhibittranscription to be identified. The choice of the promoter depends onthe type of the in vitro-transcription system (for instance yeast, HeLaor fungal cell extracts) and the RNA polymerase used.

The herein-described method permits the determination of whethertranscription is inhibited or activated in general, or remainsunaffected. The mechanism or the principle of the influence exerted by aspecific substance of a compound library is the subject matter of thesubsequent tests.

Preferably, the DNA sequence encoding the ribozyme is a linearizedvector in which transcription can be terminated by cleavage of thetemplate DNA downstream the ribozyme-encoding DNA with the use of asuitable restriction enzyme. Alternatively, the ribozyme-encoding DNAsequence is operatively linked to a termination signal for transcriptionin in-vivo application. Such termination signals are known to a skilledperson. A general prokaryotic stop signal of transcription is a GC-richregion of particular symmetry which is followed by an AT-rich sequence(A. Wu and T. Plaft, Proc. Natl. Acad. Sci. 75 (1978), 5442-5446). Forthe eukaryotic Pol II, too, there are stop signals allowingtranscription to be terminated at a defined site.

In another embodiment of the invention, the ribozyme-encoding DNA isinserted optionally together with the other above-discussed sequences,into a vector permitting the inserted DNA to propagate in a suitablehost. Vectors suitable for propagation in prokaryotic or eukaryoticsystems are for instance pBR322, pNEB193, pUC18, pUC19 (Biolabs, USA)(J. Sampson and O. Uhlenbeck, Proc. Natl. Acad. Sci. USA 85 (1988),1033-1037).

The above-described ribozymes (preferably hammerhead ribozymes orhammerhead ribozyme variants) can be used as direct reporters forquantifying transcription rates in in-vitro transcription systems. Here,the reporter RNA is endogenously produced, i.e. by transcription of thecoding gene, for instance from a suitable transcription vector.

The compositions according to the invention preferably containstabilized ribozymes, thus ensuring a longer lifetime of the ribozyme,for instance in in-vitro transcription systems. Here, the ribozyme istranscribed together with stabilizing sequences, which imitate theso-called “capping structures”, and in this way increase the stabilityof the RNA to exonuclease degradation (Gene Therapy 4 (1996), 45-54; M.Sioud et al., J. Mol. Biol. 223 (1992), 831-835).

The term “oligonucleotide substrate” as used herein relates to anyoligonucleotide, preferably RNA, which can be cleaved by the ribozyme,the cleaved oligonucleotide substrate is distinguishable from thenon-cleaved oligonucleotide substrate and a directly measurable signalis produced.

The substrate for instance carries an anchorage group at one of its end,which permits its immobilization on a suitable matrix, and a reportergroup at its other end which serves to detect the immobilized(non-cleaved) substrate. If the ribozyme is absent, the substrateremains intact and can be easily detected after its immobilization onthe matrix, because the anchorage group continues to be linked to thereporter group. By contrast, if the ribozyme is present, thereporter-specific signal cannot be detected, because the reporter groupwas separated from the anchorage group as a result of the cleavage ofthe substrate. As an alternative to the anchorage group (e.g. biotin),complementary sequence hybridization can also be used to immobilize thesubstrate, if the cleavage site and reporter group lie beyond thehybridization site. Easily detectable reporter groups which can beeasily coupled to nucleic acid ends are for instance ³²P, dye moleculesand molecules which can be detected with labeled antibodies.

The oligonucleotide substrate of the invention is essentiallycomplementary to the sequence(s) of the ribozyme which is/areresponsible for substrate bonding, i.e. it possesses a complementaritywhich permits an annealing to the ribozyme in such a way that aneffective and specific cleavage of the oligonucleotide substrate isensured: The oligonucleotide substrate is preferably fully complementaryto the ribozyme sequences responsible for substrate binding. The lengthof the region of the oligonucleotide substrate annealing to the ribozymeamounts to preferably 5 to 8 nucleotides (P. Turner, editors, Ribozymeprotocols, Humana press (1997), 151-159, 253-264). At its 5′ and/or 3′end, the oligonucleotide substrate can contain additional sequenceswhich do not participate in the annealing to the ribozyme.

In a preferred embodiment, the above-mentioned oligonucleotide substrateis double labeled, and the cleaved substrate is easily distinguishablefrom the intact substrate.

In addition to the ribozyme-encoding DNA, the in-vitro transcriptionbatch for instance contains a terminally biotinylated substrateoligonucleotide, the other end of which is labeled with fluorescein.After a minimum incubation time, sufficient for cleaving the substratein the case of unhampered transcription, transcription is stopped. Thetranscription batch is subsequently incubated with a streptavidin-coatedsolid phase (for instance with a commercially available microtiterplate) in order to enable the biotinylated substrate end to couple tothe streptavidin matrix. After removal of the transcription batch andwashing of the matrix, the latter is measured. In the case ofundisturbed (i.e. non-inhibited) transcription, no fluorescein-specificfluorescence or only a weak unspecific background fluorescence ismeasurable, as the fluorescein-labeled fragment could not beimmobilized. By contrast, if none or only a reduced transcription of theribozyme occurs, for instance because of inhibition by a transcriptioninhibitor, the portion of the non-cleaved immobilized substrate can bequantified by measurement of the fluorescein-specific fluorescence.

A method for performing a time-dependent kinetic analysis of ribozymeswithin hours is provided by the use of FRET oligonucleotides (K. J.Livak, S. J. A. Flood, J. Marmaro, W. Giusti, K. Deetz, PCR Meth. Appin.(1995), 4, 357-362) (FRET=Fluorescence Resonance Energy Transfer) (J. R.Lakowicz, Principles of Fluorescent Spectroscopy; Plenum Press, New York(1983)).

RNA oligonucleotides or DNA-RNA hybrids wherein a fluorophore group(e.g. FAM=6-carboxy-fluorescein, TET=tetrachloro-6-carboxy-fluoresceinor HEX=hexachloro-6-carboxy-fluorescein) and a correspondingfluorescence-quenching group, a so-called “quencher” (e.g.sulforhodamine 101 or TAMRA=6-carboxytetramethylrhodamine) are soarranged in spatial proximity that the fluorescence of the fluorophoreis effectively quenched are particularly preferred as FRET substrates(Lakowicz, Principles of Fluorescence Spectroscopy, Plenum

Press, New York (1983), 303-339; V. Förster, Annals of Physics (Leipzig)2 (1948), 55-75). After cleavage of the substrate by ribozyme-catalyzedhydrolysis of a particular phosphodiester bond, the fragments can driftapart in solution: The fluorescence of the fluorophore is now no longerintramolecularly quenched. Hence, if the transcription of the reporterribozyme takes place in the presence of such double labeled substrates,the transcription rate can be quantified via the amount of ribozyme(=mRNA of the reporter gene), because a measurable fluorescence signalis generated at the cleavage of the substrate. Under suitable conditions(for instance excess of substrate) the unquenched fluorescence isproportional to the amount of transcribed reporter ribozyme and theincubation time, and can be quantified via suitable automated read-outdevice.

As the increase in fluorescence is directly correlated to the cleavagerate, the system is suitable for a sensitive, non-radioactive and fastanalysis of ribozyme activities. A FRET substrate (SLI) was constructedon the basis of a known HHR/substrate complex (M. Fedor, O. C.Uhlenbeck, Proc. Natl. Acad. Sci. USA (1990), 87, 1668-1672) and wasused for a time-dependent measurement of ribozyme activity (HHR1). Aninactive HHR mutant (HHR1mut) with identical substrate binding sites wasused as a reference and negative control. The Michaelis-Menten parameterof HHR can be obtained in a single experiment by measurement of thecleavage-caused rise in fluorescence at different substrateconcentrations. FIG. 2b shows the Eadie-Hofstee plot for determining theK_(cat)/K_(M) values as the result of this measurement.

In order to determine the influence of the FAM/TAMRA labeling on thecleavage efficiency, the kinetic parameters were determined in aconventional manner with a ³²p labeled substrate without FRET labeling(S1) (FIG. 2a). The conventional method includes the separation ofcleavage products by polyacrylamide gel electrophoresis and thesubsequent evaluation of the gels by autoradiography (P. Hendry, M. J.McCall, T. J. Lockett, Characterizing ribozyme cleavage reactions; P. C.Turner (editors); Humana Press: Totowa, N.J. (1997), vol. 74, 221-229).

Both the K_(cat) and the K_(M) values were found to be in the same orderof magnitude for both substrates (S1, SL1), which shows that the FRETsubstrate is very suitable for the purpose pursued.

In order to find out whether the method is suitable for the fastcharacterization of ribozymes, the activity was measured in parallelbatches while various physico-chemical parameters were modified.

FIG. 3a shows the time-dependent course of cleavage as a result of atypical measurement. FIGS. 3b-d show the dependency of the reaction rateon the pH value, the temperature and the Mg²⁺ concentration. Under theconditions chosen here, a pH optimum was determined at a value of 8, theoptimum of [Mg²⁺] was achieved at 8 mM. The relatively low temperatureoptimum of 32° C., presumably reflects the relatively weak binding ofthe substrate to the ribozyme. The latter could be attributable to theshort hybridization regions containing only five G-C base pairs with asimultaneously relatively low Mg²⁺ concentration (4.0 mM).

In order to eliminate measurement inaccuracies caused by the equipmentor unspecific fluorescence effects (e.g. fluctuation of the signal onaccount of temperature variations), the data points obtained werecorrected by the ribozyme-independent reference values obtained with theinactive mutant HHR1mut. Moreover, the correction procedure also enabledthe determination of the activity of ribozymes produced in situ in thepresence of cell nucleus extracts.

FIG. 4 shows the measurement results of a T7 RNA polymerase dependenttranscription of ribozyme-encoding DNA templates in the presence of HeLacell nucleus extracts. As a control, parallel measurements were made onthe one hand in the absence of the T7RNA polymerase, and on the otherwith the inactive HHR mutant. Both curves show a slight rise in thefluorescence, which is presumably attributable to an unspecific cleavageof the substrate by nucleases in the cell extract. Another curvedescribes the absolute fluorescence obtained in the measurement inin-situ HHR1-production. Still another curve shows the same measurementcorrected by the superimposing background reactions (see example 2).

As expected, the corrected curve shows a sigmoidal course reflecting thesteady increase in the ribozyme concentration in the course of thetranscription reaction. These results show that it is in principlepossible to use the ribozymes as reporters for measuring transcriptionrates in vitro and in vivo. Such a reporter system can for instance beused for high throughput screening of combinatory substance librariesfor inhibitors of transcription factors, because it can be used in afully automated way and without additional pipetting steps.

DNA oligonucleotides analogous to the above-described RNAoligonucleotide substrates are commercially available (e.g. from PEApplied Biosystems, Foster City, Calif., USA) or are accessible by asimple synthesis (Livak et al., PCR Methods Appl. 4 (1995) 1-6 andRudert et al., BioTechniques 22 (1997) 1140-1145). For instance, thedouble labeled DNA oligonucleotides are used for the semiquantitativeanalysis of PCR-amplified DNA (Taqman®, PE Applied Biosystems, FosterCity, Calif. USA; see for instance also Lang et al., J. Immun. Methods203 (1997), 181-192). The Taqman® -PCR technique utilizes the intrinsic5′→3′ nuclease activity of the Taq polymerase enzyme: Duringamplification, the 5′ and 3′ double labeled DNA oligonucleotide ishydrolyzed by the enzyme. After cleavage of the DNA probe, thefluorophore and the quencher diffuse divergently, resulting in theelimination of fluorescence quenching. Subsequently, the fluorescence ofthe fluorophore is measured and serves as a yardstick for theamplification achieved (Livak et al., Research News (1995), PA AppliedBiosystems, Foster City, Calif., USA).

Similarly to the above-described application of double labeled DNAoligonucleotides, the use of corresponding RNA-based substrates can berealized without any problems. Methods for labeling ribonucleic acidswith fluorophore or fluorescence-quenching groups and techniques formeasuring the energy transfer (quenching) have already been described indetail (Turner (editors), Ribozyme protocols, Humana press (1997),241-251). The synthetic and enzymatic preparation of ribozymes and thepreparation of linearized transcription vectors are also known to askilled person (Turner (editors), Ribozyme protocols, Humana press(1997) 51-111). 5′-fluorophore- and 3′-quencher-labeled RNAoligonucleotides are commercially available just as the analogous DNAoligonucleotides (e.g. 5′-FAM and 3′-TAMRA labeled RNA from Eurogentec,Belgium). Labeling is advantageously performed at the RNA ends in ordernot to exert any influence on the hybridization of the ribozyme.

In order to avoid fluorescence emission accompanied by undesiredcleavage (for instance by nucleases in the transcription system), theuse of nuclease-resistant oligonucleotide substrates is particularlyadvantageous (Eaton and Pieken, Annu. Rev. Biochem. 64 (1995), 837-863and Shimayama et al., Nucleic Acids Res. 21 (1993), 2605-2611). This isparticularly advantageous in view of in-vivo applications where thedouble labeled substrate is exogenously introduced by suitabletechniques (for instance microinjection, liposome transport, etc.) intocells (P. Turner (editors), Ribozyme protocols, Humana press (1997),417-451). Thus, in a particularly preferred embodiment, the doublelabeled substrates are modified RNA oligonucleotides. As long as thecleavage site in the substrate is NUH↓ (according to the IUB code: N=anybase, H=A, U or C), the substrate can contain desoxyribonucleotidesor/and modified bases or/and 2′-modified ribose units. In this way, thestability of the substrate in the cell extract is increased (N. Tayloret al., Nucleic Acids Res. 20 (1992), 4559-4565). Also, the use ofinternally labeled, instead of terminally labeled oligonucleotidesubstrates can contribute to an improved signal-noise ratio, asfluorescence-quenching is increased inter alia by shorter intervalsbetween the two groups (fluorophore and quencher).

The present invention also relates to a method for the quantitativedetermination of transcription rates, which comprises the followingsteps:

(a) contacting the above-described composition with an in-vitrotranscription system under conditions at which the transcription of theDNA sequence encoding the ribozyme occurs and at which the ribozyme iscatalytically active; and

(b) measurement of the amount of cleaved oligonucleotide substrate afterand/or for a suitable period of time.

Hereinafter, the basic procedure to utilize the invention as a simplescreening method for identifying transcription inhibitors fromcombinatory substance libraries is described.

(a) Selection and Preparation of the Ribozyme-encoding DNA and theDouble Labeled Oligonucleotide Substrate.

Ribozyme-encoding DNA sequences are known to a skilled person. Dependingon the desired ribozyme type and the matching oligonucleotide substratesequence, the DNA sequence encoding the ribozyme of the invention can beprepared according to techniques known to a skilled person.

Here, either a double-stranded PCR-DNA or a linearized vector serves asa template for the in-vitro transcription of the ribozyme. Methods forpreparing corresponding templates are known to a skilled person (Turner(editors), Ribozyme protocols, Humana press (1997), 69-78 and 121-138).

Hammerhead ribozymes are particularly preferred. As the pH, temperature,Mg²⁺ concentration and the type and length of the substrate bindingsequences greatly influence the ribosome activity, it is necessary toselect that combination of ribozyme and substrate which leads tooptimized conversion rates under the physiological conditions of therespective test system. Suitable procedures are known to a skilledperson.

A hammerhead ribozyme possessing good intermolecular cleavage propertiesin respect of the complexed substrate RNA (K_(cat)/K_(m)=0.032 nM⁻¹min⁻¹ at pH 7.5, 10 mM MgCl₂, 25° C.) is described in Fedor and O.Uhlenbeck, Proc. Natl., Acad. Sci. USA 87 (1990); 1668-1672: 5′-GGG UCCUCU GAU GAG GGC CGU UAG GCC GM ACU CC-3′(SEQ ID NO: 1) (ribozyme) and5′-GGG AGU CAG GAU-3′(SEQ ID NO: 2) (substrate). For instance,advantageous hammerhead ribozyme variants and corresponding substratescan be designed on the basis of these sequences (see example 1).

In the design of the ribozyme, attention should be paid not only to thekinetic parameters but also to the fact that apart from the verypromoter sequence the transcribed region (of up to 10 nucleotides)directly following the promoter often has a decisive influence on thetranscription rates. As the 5′-transcribed sequence is, as a rule,identical with a part of the substrate hybridization region, specialcare should be taken in the design of the ribozyme and substratesequences to ensure that both optimal transcription and ribozymesubstrate hybridization are enabled. Moreover, in the choice of thedouble labeled substrate sequence the following points must inparticular be bome in mind:

The NUH cleavage (restriction) site is advantageously GUC or AUC.

The emission spectrum of the fluorophore overlaps with the absorptionspectrum of the quencher dye.

The substrate should not form intramolecular secondary structures, wherepossible.

The 5′-terminal base should not be guanosine.

Advantageously, the substrate should symmetrically hybridize to theribozyme over 12 to at the most 16 nucleotides.

(b) The preparation of the In-vitro-transcription System.

The preparation of cell extracts which are used as in-vitrotranscription systems is known to a skilled person. It is also known toa skilled person that in-vitro transcriptions can be carried out inthese cell extracts. An example of a suitable in-vitro transcriptionsystem is the class II system of human cell nucleus extracts (Matsui etal., J. Biol. Chem. 255 (1980), 11992-11996;and Roeder, Trends Biochem.Sci. 21 (1996), 327-335). Under physiological conditions, the activityof hammerhead ribozymes is, as a rule, high enough, but can be increasedfor instance by an increase in the Mg²⁺ concentration to 5 to 10 mM. Asa rule, this has no influence on transcription.

(c) Carrying Out the Reaction.

A suitable DNA template enabling the transcription of the desiredribozyme is added to the cell extract. Advantageously, an excess amountof the oligonucleotide substrate is added to the batch, in order toensure linear, reproducible dependencies between the accumulatedreporter ribozyme and the signal measured (preferably a fluorescencesignal) during the period of measurement. A parallel measurement ofdifferent transcription batches can be made for instance in commerciallyavailable 96-well microtiter plates. After addition of the potentialinhibitors or activators to be tested, the in-vitro transcription isthen started for instance by the addition of the corresponding RNApolymerase. Suitable reaction times are within the range of about 1minute to about 60 minutes.

The transcription rate is measured by the determination of thefluorescence coupled to the amount of cleaved oligonucleotide substrate.The actual amount of transcribed RNA can be determined incorrespondingly calibrated systems. Calibration can be made in thefollowing manner: Known amounts of ribozyme-encoded DNA are incubatedwith known amounts of double labeled substrate. Here, transcriptiontakes place in the presence of ³²P-α-UTP which is incorporated into theribozyme RNA formed. The rise in fluorescence is then measuredtime-dependently in identical batches, with the individual batches beingstopped at different times. For a quantification of the resultingribozyme amounts, the batches are separated on a denaturatingpolyacrylamide gel and evaluated by means of a phosphorus imager. Theamount of ribozyme can then be determined for each measurement point viathe rate of radio nucleotide incorporation. Finally, the calibrationcurve for the subsequent measurements is obtained by plotting therelative fluorescence measured against the ribozyme concentrationmeasured.

(d) Measurement of Transcription Rates and Evaluation.

If oligonucleotide substrates labeled with a fluorophore group and afluorescence quenching group are used, the emitted fluorescence isadvantageously measured in an automated manner by means of a suitableread-out device (for instance ABI Prism 770 Sequence Detection System,Perkin Elmer). Calibration methods and methods for measuring the veryfluorescence have been described in detail as have programs forcomputer-aided data processing (textbook on ABI Prism 770 SequenceDetection System, Perkin Elmer; Rudert et al., BioTechniques 22 (1997)1140-1145). In principle, the fluorescence of the fluorophore isrecorded for each transcription batch time-dependently above thebackground (ΔR_(n) value). The evaluation can be carried outsubsequently at the very ABI Prism 7700 device, by comparing the spectraof the different batches at different times with the spectrum of theuninhibited reference.

Moreover, the present invention relates to a method for identifyingtranscription-inhibitors or transcription activators, which comprisesthe following steps:

(a) contacting the above-described composition with a first in-vitrotranscription system and a second transcription system containing thecompound to be tested, under conditions at which the transcription ofthe DNA sequence encoding the ribozyme occurs and at which the ribozymeis catalytically active; and

(b) measuring the amount of cleaved oligonucleotide substrate afterand/or for a suitable period of time in both transcription systems, witha higher transcription rate in the second transcription systemsuggesting the presence of a transcription activator and a reducedtranscription rate suggesting the presence of a transcription inhibitor.

The basic procedure is identical to the above-described procedure, withthe exception that not only one test system is used but two, which onlydiffer in one point, i.e. in that the second test system contains thecompound to be tested.

After evaluation of the data, the effect of the addition of thesubstance on the transcription rate relative to the reference(=uninhibited transcription) can be determined: A lower fluorescencesignal suggests inhibition, a higher signal suggests the presence of atranscription activator.

In order to further increase the utility of the above-describedribozymes and the sensitivity of the above-described method, it ispossible to apply “in-vitro selection” (Pan, Curr. Op. Chem. Biol. 1(1997), 17-25; Breaker, Chem. Rev. 97 (1997), 371-390) and ribozymeengineering techniques (Turner (editors), Ribozyme protocols, Humanapress (1997) 11-15,141-159, 253-273). This allows particularly effectivede novo ribozymes or variants of natural ribozymes to be prepared, inorder to achieve optimum conversion rates with the non-naturaloligonucleotide substrate under the corresponding conditions of thein-vitro transcription system (S. Santoro and G. Joyce, Proc. Natl.Acad. Sci. USA 94 (1997), 4262-4266).

This in-vitro selection has recently been successfully used to produceribozymes possessing modified substrate specificities and activities(Vaish, Biochemistry 36 (1997), 6495-6501, and Berzal-Herranz et al.,Gene Dev. 6 (1992), 129-134). In this connection, the in-trans selectionof ribozymes is a particularly advantageous method, with a directselection for cleavage of the double labeled oligonucleotide substrate(Ishizaka, Biochem. Biophys. Research Com. 214 (1995), 403-409). Fromthe ribozyme sequences obtainable by this method, those ribozymes whichshow the desired property in the automated fluorescence screening of thecell extracts can be directly selected.

Hence, the present invention also relates to the above-describedcomposition which contains a DNA sequence encoding an in-vitro-selectedribozyme.

Moreover, the present invention relates to the use of theabove-described composition for absolute or comparative measurement oftranscription rates, preferably by means of the above-described method.

Moreover, the invention relates to the use of the method of theinvention for measuring the catalytic activity of ribozymes.

Finally, the present invention relates to kits containing theabove-described compositions, preferably for carrying out the method ofthe invention. Kits, also containing an in-vitro transcription system,for instance one of the above-described systems are preferred accordingto the invention.

DESCRIPTION OF THE FIGURES

FIG. 1:

A schematic representation of the composition of the invention (in-vitroreporter system). (1) Production of the ribozyme byin-vitro-transcription in the cell extract. A corresponding DNAsequence, for instance deriving from a vector, serves as a template. (2)The binding of the double labeled substrate (for instance 5′-FAM and3′-TAMRA labeled RNA) to the ribozyme leads to the formation of thecatalytically active complex. The fluorescence is intramolecularlyquenched in the substrate. (3) Cleavage of the double labeled substrate.(4) Dissociation of the reaction products from the ribozyme. Afluorescence signal hv is measured on account of the elimination of thequenching effect.

FIG. 2:

Determination of the kinetic parameters of HHR1 [4 nM] at 37° C. (a)Eadie-Hofstee plot and kinetic parameters of the cleavage activity ofHHR1 with a 5′-³²P-labeled substrate (S1) not carrying any FRETlabeling. (b) Eadie Hofstee plot and kinetic parameters of the cleavageactivity of HHR1 with the FRET substrate (SL1).

FIG. 3:

Characterization of the cleavage activity at 4 nM HHR1 and 200 or 300 nMSL1. (a) Time-dependent course of cleavage with the reciprocallyexponential regression curve (only 1% of all data points measured aredepicted). (b-d) dependence of the reaction rate of the HHR1on (b) thepH, (c) the temperature and (d) the Mg²⁺ concentration. TheK_(cat)/K_(M) values at 25° C. (0.0134 nM⁻¹ min⁻¹) were also determined.

FIG. 4:

Time-dependent rise in fluorescence of in-situ-produced HHR and controlbatches in the presence of HeLa cell extracts HHR1mut-DNA+T7 RNApolymerase, HHR1-DNA without T7 RNA polymerase, HHR1-DNA+T7 RNApolymerase, HHR1-DNA+T7 RNA polymerase corrected by the unspecificbackground activities (see example 2).

THE FOLLOWING EXAMPLES EXPLAIN THE INVENTION. EXAMPLE 1 Measurement ofthe Influence of Inhibitors on the In-vitro Transcription with T7-RNAPolymerase

1. Production of the Ribozyme-encoding Template DNA and the 5′-FAM- and3′-TAMRA-labeled Substrate RNA

The ribozyme-encoding DNA sequence HHR1-DNA described in this exampleand the RNA substrate SL1 are derived from a known hammerhead ribozymesubstrate complex (M. Fedor and O. Uhlenbeck, Proc. Natl. Acad. Sci. USA87 (1990), 1668-1672). The template for the in-vitro transcription ofthe ribozyme HHR1, the ribozyme-encoding double-stranded HHR1-DNA wasproduced by polymerase chain Reaction (PCR). For this purpose, the sensestrand of the ribozyme, including the 5′-terminal T7-promoter sequence,was synthesized with an Expedite Oligonucleotide Synthesizer (Millipore,USA): 5′-TCT AAT ACG ACT CAC TAT A GGG TCC TCT GAT GAG GCC GTT AGG CCGAAA CTC GT-3′(SEQ ID NO: 3) (HHR1-DNA); the primer binding sites arewritten in italics). The synthesis of the antisense strand and theamplification of the double stranded template were carried out the useof the following primers: 5′-TCT AAT ACG ACT CAC TAT A-3′(SEQ ID NO: 4)(5′ Primer) and 3′-GG CM TCC GGC m GAG CA-5′(SEQ ID NO: 5) (3′ Primer).A typical 100 μl reaction contained 10 mM tris-HCL, pH 8.9, 100 mM KCl,1.5 mM MgCl₂, 50 mg/ml bovine serum albumin, 0.05% Tween 20(v/v), 200 μMdA/dC/dG/dTTP. 2 μM of 5′ and 3′ primers, about 200 nM of singlestranded DNA template and 2.5 units of the Tth DNA polymerase.Amplification was carried out according to the manufacturer's protocol(Boehringer Mannheim, Tth-DNA polymerase Kit) in four to five PCR cyclesa 95° C., 55 seconds; 55° C., 1 minute; 72° C., 1 minute. The amplifiedDNA was subsequently isolated according to standard methods and purifiedfrom excess primers by means of agarose gel (T. Maniatis, E. Fritsch, J.Sambrook, Molecular cloning; a Laboratory Manual, Cold Spring HarborLaboratory Press, New York (1982), 14.2-14.35).

Analogously, a double-stranded DNA template encoding an inactiveribozyme variant HHR1mut was prepared starting from the followingsingle-stranded DNA: 5′-TCT MT ACG ACT CAC TAT A GGG TCC TCT TAG GAG GCCGTT AGG CCA GM CTC GT-3′ (SEQ ID NO: 6) (HHR1mut; primer binding sitesare written in italics, mutations are emphasized). The following primers5′-TCT ATT ACG ACT CAC TAT A-3′ (SEQ ID NO: 7) (5′-primer) and 3′-GG CMTCC GGT CTT GAG CA-5′ (SEQ ID NO: 8) (3′-primer) were used.

The 5′-FAM and 3′-TAMRA labeled substrate RNA SL1 having the sequence5′-FAM-ACG AGU CAG GAU U-TAMRA-3′(SEQ ID NO: 9) was purchases fromEurogentec gel (P. Turner (editors), Ribozyme protocols, Humana Press(1997) 79-81).

2. In Vitro Transcription

A typical 50 μl reaction batch contained: 40 mM tris HCl, pH 8.0, 50 mMNaCl, 2 mM spermidin, 5 mM dithiothreitol, 5 to 25 mM MgCl₂, about 500nM SL1, 0.2 to 2 μM HHR1-DNA or HHR1mut-DNA, 4 mM A/C/G/UTP and 50 unitsof T7-RNA-polymerase. It is important to ensure that onlydouble-stranded DNA is used in transcription, as both single-strandedsense-strand DNA and 3′-primer DNA can inhibit the cleavage reaction.In-vitro transcription was started by the addition of the polymerase,and incubation was carried out at 37° C. while the measurement wastaken.

3. Real Time Measurement of Fluorescence at Cleavage of SL1 by HHR1:

The fluorescence of the transcription batches was measured in anautomated manner in an ABI Prism 770 spectrometer (Applied Biosystems,USA), the temperature of which could be adjusted. The spectra in theemission wavelength range of the two dyes (FAM, λ_(max)=518 nm andTAMRA, λ_(max)=582 nm) were recorded in intervals of 7 seconds(excitation energy=488 nm). After an incubation time of 3 hours, thecollected data were evaluated by the software contained in theequipment. For a real time control of the individual transcriptions, thefluorescence spectra (range of 500 nm to 660 nm) were projectedtime-dependently over the spectrum of the reference transcription (withnon-functional HHR1mut DNA). Under optimum transcription conditions adistinct increase in the FAM specific fluorescence could be seen inbatches with HHR1-DNA relative to the constant fluorescence of thereference transcription with HHR1mut-DNA. Subsequently, the portion ofcleaved substrate RNA relative to the negative control (identical batchwith inactive HHR1mut-DNA instead of HHR1-DNA) was determined byplotting the relative fluorescence of the fluorophore (ΔR_(n) value) at535 nm versus time. Methods for calibrating the equipment and programsfor computer-aided data processing have been described in detail(textbook on ABI Prism 770 Sequence Detection System, Perkin Elmer; W.Rudert et al., BioTechniques 22 (1997) 1140-1145). As expected, theevaluation of the measurement data for a substrate concentration of 900nM SL1 showed that the relative fluorescence ΔR_(n) of the fluorophoreat a constant concentration of HHR1-DNA increased with the incubationtimes. The inactivated ribozyme HHR1mut had no influence on thefluorescence signal measured.

4. Real Time Measurement of the T7 Transcription Rates in the Presenceof T7-RNA Polymerase Inhibitors:

The measurements were carried out in a manner analogous to that under3., however with T7-lysozyme, an inhibitor of T7-RNA-polmyerase (R.Ikeda, P. Bailey, J. Biol. Chem. 267 (1992), 20153-20159). As expected,ΔR_(n) decreased relative to the non-inhibited transcription with anincreasing inhibitor concentration.

EXAMPLE 2 Determination of the Activity of In-situ-produced Ribozymes inthe Presence of Cell Nucleus Extracts

1. Preparation of the Substrate RNA

The preparation was carried out as described in Example 1.1.

2. Measurement of the Ribozyme Activity

A typical 50 μl reaction batch for the in-vitro transcription for theribozyme production contained 40 mM tris HCl, pH 8.0, 50 mM NaCl, 2 mMspermidin, 5 mM dithiotreitol, 8 mM MgCl₂, 0.2-2 μM HHR1-DNA orHHR1mut-DNA, 4 mM A/C/G/UTP, 40 units of RNAsin (Promega, Madison, Wis.)and 50 units of T7 RNA polymerase (Stratagene, Heidelberg). The RNA waspurified by means of a 16% denaturing polyacrylamide gel (37.5:1). Forthe measurement of the ribozyme activity of in-situ-produced HHR1 thebatch additionally contained 100 nM SL1 and 10 units of HeLa nucleusextract (HeLa Cell Extract Transcription System, Promega, Madison,Wis.). The in-vitro transcription was started by the addition of thepolymerase and nucleus extract and incubation was carried out at 37° C.while the measurement was taken.

The real time measurements of the rise in fluorescence caused by theribozyme were taken in 50 μl reaction batches. The signal measuredcomprises both the chemical step of cleavage and the release of thecleavage products. The fluorescence of the transcription batches wasmeasured in an automated manner in an ABI Prism 770 spectrometer(Applied Biosystems, USA), the temperature of which could be adjusted.At intervals of 0.5-0.7 s the spectra in the emission wavelength rangeof the two dyes (FAM, λ_(max)=535 nm and TAMRA, λ_(max)=582 nm) wererecorded (excitation energy 488 nm). All measurements were tripletdeterminations. Subsequently, the portion of cleaved substrate RNArelative to the negative control (identical batch with inactiveHHR1mut-DNA instead of HHR1-DNA) was determined by plotting the relativefluorescence of the fluorophore (ΔR_(n) value) at 535 nm versus time.The rough data were imported into Microsoft Excel, processed, andsubsequently evaluated by means of the program KaleidaGraph (AbelbeckSoftware, Munich).

In order to eliminate unspecific fluorescence effects of the measurementit was necessary to take into account that at a rise in fluorescencethrough catalytic cleavage the absolute fluorescence variationsincrease, while their percentage variations do not. The course ofcleavage from an aspect of time was corrected on the basis of the curvemeasured for the negative controls and their percentage deviation fromthe initial value from an aspect of time was corrected in accordancewith the equation (1):

F _(korr)(t)=F _(neg)(t)/F _(neg)(t ₀)×F _(HHR)(t)   (1)

[F_(korr)(t): corrected fluorescence at time t; F_(neg) (t):fluorescence of the negative control at time t; F_(neg) (t_(o)):fluorescence of the negative control at time t=0; F_(HHR)(t): rise influorescence measured in the presence of transcribed HHR at time t].

9 1 35 RNA Unknown Sequence derived from hammerhead ribozyme 1ggguccucug augagggccg uuaggccgaa acucc 35 2 12 RNA Unknown substrate ofSEQ ID NO 1 2 gggagucagg au 12 3 54 DNA Artificial Sequence PCR Primerderived from hammerhead ribozyme 3 tctaatacga ctcactatag ggtcctctgatgaggccgtt aggccgaaac tcgt 54 4 19 DNA Artificial Sequence PCR Primerderived from hammerhead ribozyme 4 tctaatacga ctcactata 19 5 19 DNAArtificial Sequence PCR Primer derived from hammerhead ribozyme 5ggcaatccgg ctttgagca 19 6 54 DNA Unknown derived from ribozyme variantHHR1mut 6 tctaatacga ctcactatag ggtcctctta ggaggccgtt aggccagaac tcgt 547 19 DNA Artificial Sequence PCR Primer derived from ribozyme variantHHR1mut 7 tctattacga ctcactata 19 8 19 DNA Artificial Sequence PCRPrimer derived from ribozyme variant HHR1mut 8 ggcaatccgg tcttgagca 19 913 RNA Unknown Substrate RNA SL1 purchased from Eurogentec (Belgium) 9acgagucagg auu 13

What is claimed is:
 1. A reporter system comprising: (a) a firstoligonucleotide encoding a ribozyme; and (b) a second oligonucleotidewhich is a substrate oligonucleotide for the ribozyme, said secondoligonucleotide comprising a label capable of generating a directlymeasurable signal only when said second oligonucleotide substrate iscleaved by said ribozyme.
 2. The reporter system according to claim 1,wherein the first oligonucleotide encodes a hammerhead ribozyme.
 3. Thereporter system according to claim 1 or 2, wherein the firstoligonucleotide is inserted into a vector.
 4. The reporter systemaccording to claim 1 or 2, wherein the first oligonucleotide and thesecond oligonucleotide are resistant to nuclease.
 5. The reporter systemaccording to claim 1 or 2, wherein the second oligonucleotide is adouble labeled oligonucleotide substrate.
 6. The reporter systemaccording to claim 5, wherein the double labeled oligonucleotidesubstrate contains a fluorophore group and a fluorescence-quenchinggroup and wherein after cleavage of said second oligonucleotide by theribozyme the fluorescence of the fluorophore is not quenched by thefluorescence-quenching group.
 7. The reporter system according to claim6, wherein the fluorophore group is 6-carboxy-fluorescein (FAM) and thefluorescence-quenching group is 6carboxy-tetramethyl-rhodamine (TAMRA).8. The reporter system according to claim 1 or 2, wherein said firstoligonucleotide encodes an in-vitro selected or non-natural ribozyme. 9.A kit containing the reporter system claims 1 or
 2. 10. The kitaccording to claim 9, additionally containing an in-vitro transcriptionsystem.
 11. A method for the quantitative determination of transcriptionrates, which comprises the following steps: (a) contacting (1) areporter system comprised of a first oligonucleotide encoding a ribozymeand a second oligonucleotide which is a substrate for said ribozyme,said second oligonucleotide comprising a label capable of generating adirectly measurable signal only when said second oligonucleotidesubstrate is cleaved by said ribozyme, with (2) an in vitrotranscription system under conditions at which transcription of theribozyme-encoding DNA sequence occurs and at which the ribozyme iscatalytically active; and (b) measuring the amount of cleavedoligonucleotide substrate by measuring said signal.
 12. A method foridentifying transcription-inhibitors or transcription activators whichcomprises the following steps: (a) contacting (1) a reporter systemcomprised of a first oligonucleotide encoding a ribozyme and a secondoligonucleotide which is a substrate for said ribozyme, said secondoligonucleotide comprising a label capable of generating a directlymeasurable signal only when said second oligonucleotide is deaved bysaid ribozyme, with (2) a first in vitro transcription system and (3) asecond transcription system which contains a compound to be tested,under conditions at which transcription of the first oligonucleotideoccurs and at which the ribozyme is catalytically active; and (b)measuring the amount of cleaved oligonucleotide substrate by measuringsaid signal in the two transcription systems, with a highertranscription rate in the second transcription system being indicativethat said compound to be tested is a transcription activator and areduced transcription rate being indicative that said compound to betested is a transcription-inhibitor.
 13. A method for measuring thecatalytic activity of ribozymes which comprises: (a) contacting (1) areporter system comprised of a first oligonucleotide encoding a ribozymeand a second oligonucleotide which is a substrate for said ribozyme,said second oligonucleotide comprising a label capable of generating adirectly measurable signal only when said second oligonucleotide iscleaved by said ribozyme, with (2) an in vitro transcription systemunder conditions at which the transcription of the ribozyme-encoding thefirst oligonucleotide occurs and at which the ribozyme is catalyticallyactive; and (b) measuring the amount of cleaved oligonucleotidesubstrate by measuring said signal.
 14. A method for measuring thecatalytic activity of ribozymes which comprises the following steps: (a)contacting (1) a reporter system comprised of a first oligonucleotideencoding a ribozyme and a second oligonucleotide which is a substratefor said ribozyme, said second oligonucleotide comprising a labelcapable of generating a directly measurable signal only when said secondoligonucleotide is cleaved by said ribozyme, with (2) a first in vitrotranscription system and (3) a second transcription system whichcontains a compound to be tested, under conditions at whichtranscription of the ribozyme-encoding DNA sequence occurs and at whichthe ribozyme is catalytically active; and (b) measuring the amount ofcleaved oligonucleotide substrate by measuring said signal in the twotranscription systems with a higher transcription rate in the secondtranscription system being indicative that said compound to be tested isa transcription activator and a reduced transcription rate beingindicative that said compound to be tested is a transcription inhibitor.15. A reporter system comprising: (a) a first oligonucleotide encoding aribozyme which is operably linked to a promoter and/or regulatoryelements; and (b) a second oligonucleotide which is a substrateoligonucleotide for the ribozyme, said second oligonucleotide comprisinga label capable of generating a directly measurable signal only whensaid second oligonucleotide substrate is cleaved by said ribozyme. 16.The reporter system according to claim 15, wherein the firstoligonucleotide encodes a hammerhead ribozyme.
 17. The reporter systemaccording to claim 15 or 16, wherein the first oligonucleotide isinserted into a vector.
 18. The reporter system according to claim 15 or16, wherein the first oligonucleotide and the second oligonucleotide areresistant to nuclease.
 19. The reporter system according to claim 15 or16, wherein the second oligonucleotide is a double labeledoligonucleotide substrate.
 20. The reporter system according to claim19, wherein the double labeled oligonucleotide substrate contains afluorophore group and a fluorescence-quenching group and wherein aftercleavage of said second oligonucleotide by the ribozyme the fluorescenceof the fluorophore is not quenched by the fluorescence-quenching group.21. The reporter system according to claim 20, wherein the fluorophoregroup is 6carboxy-fluorescein (FAM) and the fluorescence-quenching groupis 6-carboxy-tetramethyl-rhodamine (TAMRA).
 22. The reporter systemaccording to claim 15 or 16, wherein said first oligonucleotide encodesan in-vitro selected or non-natural ribozyme.
 23. A method for thequantitative determination of transcription rates, which comprises thefollowing steps: (a) contacting (1) a reporter system comprised of afirst oligonucleotide encoding a ribozyme which is operably linked to apromoter and/or regulatory elements, and a second oligonucleotide whichis a substrate for said ribozyme, said second oligonucleotide comprisinga label capable of generating a directly measurable signal only whensaid second oligonucleotide substrate is cleaved by said ribozyme, with(2) an in vitro transcription system under conditions at whichtranscription of said first oligonucleotide occurs and at which theribozyme is catalytically active; and (b) measuring the amount ofcleaved oligonucleotide substrate by measuring said signal.
 24. A methodfor identifying transcription-inhibitors or transcription activatorswhich comprises the following steps: (a) contacting (1) a reportersystem comprised of a first oligonucleotide encoding a ribozyme which isoperably linked to a promoter and/or regulatory elements, and a secondoligonucleotide which is a substrate for said ribozyme, said secondoligonucleotide comprising a label capable of generating a directlymeasurable signal only when said second oligonucleotide substrate iscleaved by said ribozyme, with (2) a first in vitro transcription systemand (3) a second transcription system which contains a compound to betested, under conditions at which transcription of the firstoligonucleotide occurs and at which the ribozyme is catalyticallyactive; and (b) measuring the amount of cleaved oligonucleotidesubstrate by measuring said signal in the two transcription systems,with a higher transcription rate in the second transcription systembeing indicative that said compound to be tested is a transcriptionactivator and a reduced transcription rate being indicative that saidcompound to be tested is a transcription-inhibitor.
 25. A method formeasuring the catalytic activity of ribozymes which comprises: (a)contacting (1) a reporter system comprised of a first oligonucleotideencoding a ribozyme which is operably linked to a promoter and/orregulatory elements, and a second oligonucleotide which is a substratefor said ribozyme, said second oligonucleotide comprising a labelcapable of generating a directly measurable signal only when said secondoligonucleotide substrate is cleaved by said ribozyme, with (2) an invitro transcription system under conditions at which the transcriptionof the first oligonucleotide occurs and at which the ribozyme iscatalytically active; and (b) measuring the amount of cleavedoligonucleotide substrate by measuring said signal.
 26. A method formeasuring the catalytic activity of ribozymes which comprises thefollowing steps: (a) contacting (1) a reporter system comprised of afirst oligonucleotide encoding a ribozymes which is operably linked to apromoter and/or regulatory elements, and a second oligonucleotide whichis a substrate for said ribozyme, said second oligonucleotide comprisinga label capable of generating a directly measurable signal only whensaid second oligonucleotide substrate is cleaved by said ribozyme, with(2) a first in vitro transcription system and (3) a second transcriptionsystem which contains a compound to be tested, under conditions at whichtranscription of the first oligonucleotide occurs and at which theribozyme is catalytically active; and (b) measuring the amount ofcleaved oligonucleotide substrate by measuring said signal in the twotranscription systems with a higher transcription rate in the secondtranscription system being indicative that said compound to be tested isa transcription activator and a reduced transcription rate beingindicative that said compound to be tested is a transcription inhibitor.27. The method according to claim 11, 12, 14, 23, 24, 25, or 26, whereinsaid first oligonucleotide encodes a hammerhead ribozyme.
 28. The methodaccording to claim 11, 12, 13, 14, 23, 24, 25, or 26, wherein said firstoligonucleotide is inserted into a vector.
 29. The method according toclaim 11, 12, 13, 14, 23, 24, 25, or 26, wherein the secondoligonucleotide is a double labeled oligonucleotide substrate.
 30. Themethod according to claim 11, 12, 13, 14, 23, 24, 25, or 26, wherein thedouble labeled oligonucleotide substrate contains a fluorophore groupand a fluorescence-quenching group and wherein after cleavage of saidsecond oligonucleotide by the ribozyme the fluorescence of thefluorophore is not quenched by the fluorescence-quenching group.
 31. Themethod according to claim 30, wherein the fluorophore group is6-carboxy-fluorescein (FAM) and the fluorescence-quenching group is6carboxy-tetramethyl-rhodamine (TAMRA).
 32. The method according toclaim 11, 12, 14, 23, 24, 25, or 26, wherein said first oligonucleotideencodes an in vitro selected or non-natural ribozyme.